Insights

Innovative Product Offering BioLamina's exclusive lineup of full-length human recombinant laminins positions it as a leader in high-quality, biomimetic cell culture products. This creates opportunities to target biotech and pharma companies focused on stem cell research, regenerative medicine, and cell therapy development seeking reliable and standardized matrix solutions.

Strategic Collaborations Recent partnerships with Cell X Technologies and FyoniBio indicate a focus on enhancing reproducibility in advanced therapies and process development. These collaborations suggest potential for joint ventures or procurement channels with companies developing cell-based treatments and quality-controlled manufacturing platforms.

Funding & Expansion With recent funding of over €17 million and new executive hires, BioLamina is expanding its technological capabilities and market reach. This signals increased capacity to serve larger clients, explore new markets, and develop innovative cell culture solutions for research and therapeutics.

Global Market Presence Operating with a modest but growing team across production, R&D, and sales, BioLamina aims to compete with industry giants by emphasizing premium quality and scientific expertise. This presents a sales opportunity to target research labs and biopharma firms worldwide needing dependable cell culture matrices.

Focus on Cell Therapy BioLamina's vision to advance cell therapy aligns with the burgeoning regenerative medicine market. Business development efforts could focus on connecting with cell therapy developers, biomanufacturers, and clinical research organizations investing in standardized and xeno-free culture platforms.

BioLamina Tech Stack

BioLamina uses 8 technology products and services including Canva, Amazon S3, Cloudflare, and more. Explore BioLamina's tech stack below.

  • Canva
    Audio, Video, Graphics
  • Amazon S3
    Content Delivery Network
  • Cloudflare
    Content Management System
  • Google Maps
    Maps
  • Flywheel
    Platform As A Service
  • Animate.css
    UI Frameworks
  • Microsoft IIS
    Web Servers
  • Nginx
    Web Servers

Media & News

BioLamina's Email Address Formats

BioLamina uses at least 1 format(s):
BioLamina Email FormatsExamplePercentage
First.Last@biolamina.comJohn.Doe@biolamina.com
94%
First.Middle@biolamina.comJohn.Michael@biolamina.com
4%
First@biolamina.comJohn@biolamina.com
1%
Last.First@biolamina.comDoe.John@biolamina.com
1%

Frequently Asked Questions

What is BioLamina's phone number?

Minus sign iconPlus sign icon
You can contact BioLamina's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is BioLamina's official website and social media links?

Minus sign iconPlus sign icon
BioLamina's official website is biolamina.com and has social profiles on LinkedIn.

What is BioLamina's SIC code NAICS code?

Minus sign iconPlus sign icon
BioLamina's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BioLamina have currently?

Minus sign iconPlus sign icon
As of December 2025, BioLamina has approximately 118 employees across 2 continents, including EuropeNorth America. Key team members include Chief Executive Officer: K. L.Chief Scientific And Business Development Officer: T. K.Chief Technology Officer: B. H.. Explore BioLamina's employee directory with LeadIQ.

What industry does BioLamina belong to?

Minus sign iconPlus sign icon
BioLamina operates in the Biotechnology Research industry.

What technology does BioLamina use?

Minus sign iconPlus sign icon
BioLamina's tech stack includes CanvaAmazon S3CloudflareGoogle MapsFlywheelAnimate.cssMicrosoft IISNginx.

What is BioLamina's email format?

Minus sign iconPlus sign icon
BioLamina's email format typically follows the pattern of First.Last@biolamina.com. Find more BioLamina email formats with LeadIQ.

When was BioLamina founded?

Minus sign iconPlus sign icon
BioLamina was founded in 2009.

BioLamina

Biotechnology ResearchStockholm, Sweden51-200 Employees

BioLamina is a Swedish biotechnology company with a global presence, offering cell culture matrices for primary cells. We offer an expansive portfolio of recombinant laminin proteins for a variety of applications, including the reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types. Our chemically defined and xeno-free laminin cell culture matrices allow you to imitate the natural cell-matrix interaction in vitro. Laminins are key components of the extracellular matrix. Through their interactions with specific receptors, laminins trigger the authentic cellular responses, pivotal for cell anchorage, survival, proliferation, migration, organization, and specialization, leading to improved cell functionality.

BioLamina’s laminins are the only original full length, human, recombinant laminins on the market. Our high technology products contribute to our customer’s efficiency and scientific breakthroughs and enable them to start a new era in medical research. We are known and recognized for our premium products, competence, dedication, and service and position ourselves as being in the forefront of cell culturing. Our vision is to make BioLamina a leading brand within the field of cell culture and to help make cell therapy a reality.

BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture-based research. The company was started in 2009 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 35 employees spanning from production, R&D, logistics, sales, and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.

Section iconCompany Overview

Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
51-200

Section iconFunding & Financials

  • $1M$10M

    BioLamina's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    BioLamina's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.